AstraZeneca Shares Drop Amid Reports of Potential Merger Talks with Bristol Myers Squibb
Market analysts express confusion over the potential £300 billion tie-up, while the pharmaceutical giant sees its valuation fall by nearly £18 billion.
AstraZeneca's market value declined by nearly £18 billion following reports that the pharmaceutical company was engaged in discussions for a significant merger with U.S. rival Bristol Myers Squibb (BMS). Despite the market's negative reaction, AstraZeneca's CEO Pascal Soriot is reportedly determined to move forward with the potential deal, which could be announced imminently.
The proposed merger is expected to be primarily financed through stock rather than cash, with Morgan Stanley reportedly advising on the transaction. Sources indicate that Soriot has sought and secured provisional support from the British government by agreeing to maintain the headquarters of the combined entity in the United Kingdom.
AstraZeneca has not commented on the reports, and its shares fell 9 percent, or 1132 pence, to 11,500 pence. The stock market decline followed a Financial Times report detailing months of merger discussions between AstraZeneca and BMS. If successful, the merger would create one of the world's largest pharmaceutical companies, with an estimated valuation of approximately £300 billion.
Industry analysts have voiced skepticism regarding the rationale behind the potential merger. Michael Leuchten, an analyst at Jefferies, stated that the reasons for combining the two companies are unclear, suggesting that Astra's needs could potentially be met through other means, such as sourcing drugs from China. Leuchten also pointed out that both companies have substantial portfolios in cancer drugs, indicating that any merger would face significant regulatory scrutiny on both sides of the Atlantic.
Leuchten further commented on the political implications of the deal, noting that a UK-based company acquiring a major American pharmaceutical firm could be sensitive at a time when the U.S. is focusing on domestic manufacturing and strategic industries. He suggested that such a move would require careful navigation to mitigate potential friction.
Concerns have also been raised that AstraZeneca might shift its primary stock market listing to New York, which would represent a significant blow to the London Stock Exchange. Soriot's previous statements, including describing AstraZeneca as a "very American company," and the company's expansion of its U.S. dealings and licensing agreements in China, have fueled speculation.
The news of the potential merger surprised investors, particularly as Soriot had recently stated that the group did not require mergers or acquisitions to achieve its 2030 sales target of $80 billion. However, a successful merger would validate his earlier decision to reject a £70 billion takeover offer from Pfizer in 2014, a period when AstraZeneca was considered vulnerable to a buyout. Since that time, Soriot has been credited with improving the company's performance and increasing its value to £196 billion.